Cargando…
Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats
Objective. The study aimed to evaluate the influences of coadministration of antiepileptic drugs (AEDs) on an antimalarial candidate 99/411 pharmacokinetic (PK) profile. Method. For this, single oral dose PK drug interaction studies were conducted between 99/411 and FDA approved AEDs, namely, Phenyt...
Autores principales: | Singh, Yeshwant, Kushwaha, Hari Narayan, Misra, Anamika, Hidau, Mahendra Kumar, Singh, Shio Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212661/ https://www.ncbi.nlm.nih.gov/pubmed/25383231 http://dx.doi.org/10.1155/2014/756965 |
Ejemplares similares
-
Pharmacokinetic Study and Bioavailability of a Novel Synthetic Trioxane Antimalarial Compound 97/63 in Rats
por: Kushwaha, Hari Narayan, et al.
Publicado: (2014) -
Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99–411, with long acting prescription antimalarials, lumefantrine and piperaquine
por: Taneja, Isha, et al.
Publicado: (2015) -
Novel series of 1,2,4-trioxane derivatives as antimalarial agents
por: Rudrapal, Mithun, et al.
Publicado: (2017) -
Assay method for quality control and stability studies of a new antimalarial agent (CDRI 99/411)()
por: Khandelwal, Kiran, et al.
Publicado: (2013) -
Solvent and Substituent Effects on the Thermolysis of Antimalarial Fluorophenyl Substituted 1,2.4-Trioxanes
por: Cafferata, Lazaro F. R., et al.
Publicado: (2003)